Published in J Abnorm Psychol on May 01, 2002
Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes. Brain Cogn (2008) 0.99
A model of smooth pursuit eye movement deficit associated with the schizophrenia phenotype. Psychophysiology (2003) 0.90
Microstates in resting-state EEG: current status and future directions. Neurosci Biobehav Rev (2014) 0.87
Smooth pursuit eye movement, prepulse inhibition, and auditory paired stimuli processing endophenotypes across the schizophrenia-bipolar disorder psychosis dimension. Schizophr Bull (2013) 0.86
Reliability of resting-state microstate features in electroencephalography. PLoS One (2014) 0.81
"To see or not to see: that is the question." The "Protection-Against-Schizophrenia" (PaSZ) model: evidence from congenital blindness and visuo-cognitive aberrations. Front Psychol (2013) 0.76
The Role of Dopamine in Anticipatory Pursuit Eye Movements: Insights from Genetic Polymorphisms in Healthy Adults. eNeuro (2017) 0.75
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry (2007) 2.89
Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation (2002) 2.32
Intact attentional control of working memory encoding in schizophrenia. J Abnorm Psychol (2006) 2.28
Morphometric assessment of the heteromodal association cortex in schizophrenia. Am J Psychiatry (2004) 2.27
Depressive symptoms and heart rate variability in postmenopausal women. Arch Intern Med (2005) 2.08
Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05
Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits. Arch Gen Psychiatry (2009) 2.03
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull (2009) 1.95
Delay discounting in schizophrenia. Cogn Neuropsychiatry (2007) 1.94
Obesity development during adolescence in a biracial cohort: the NHLBI Growth and Health Study. Pediatrics (2002) 1.92
Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry (2008) 1.78
Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry (2013) 1.76
A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. Proc Natl Acad Sci U S A (2010) 1.70
Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res (2004) 1.65
Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry (2005) 1.57
Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology (2009) 1.41
Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry (2007) 1.39
Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.37
Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry (2002) 1.36
Diffusion tensor imaging white matter endophenotypes in patients with schizophrenia or psychotic bipolar disorder and their relatives. Am J Psychiatry (2013) 1.35
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry (2011) 1.33
No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology (2005) 1.29
Genetics and intermediate phenotypes of the schizophrenia--bipolar disorder boundary. Neurosci Biobehav Rev (2009) 1.26
Factor structure of the Brief Negative Symptom Scale. Schizophr Res (2012) 1.23
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry (2011) 1.22
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2011) 1.20
Impaired control of visual attention in schizophrenia. J Abnorm Psychol (2006) 1.19
Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (2010) 1.19
Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2003) 1.18
The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates. Schizophr Res (2011) 1.18
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res (2011) 1.17
Diet and sex hormones in girls: findings from a randomized controlled clinical trial. J Natl Cancer Inst (2003) 1.15
Working memory for visual features and conjunctions in schizophrenia. J Abnorm Psychol (2003) 1.11
The relationship between working memory capacity and broad measures of cognitive ability in healthy adults and people with schizophrenia. Neuropsychology (2013) 1.11
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study. Schizophr Res (2013) 1.08
Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res (2011) 1.08
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol Psychiatry (2007) 1.06
Specific motion processing pathway deficit during eye tracking in schizophrenia: a performance-matched functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.04
Gamma/beta oscillation and sensory gating deficit in schizophrenia. Neuroreport (2004) 1.04
The roles of reward, default, and executive control networks in set-shifting impairments in schizophrenia. PLoS One (2013) 1.04
Measurement of steroid sex hormones in serum: a comparison of radioimmunoassay and mass spectrometry. Steroids (2002) 1.04
Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl) (2004) 1.03
Expanding our understanding of the relationship between negative life events and depressive symptoms in black and white adolescent girls. Psychol Med (2004) 1.03
Self-perceived barriers to activity participation among sedentary adolescent girls. Med Sci Sports Exerc (2006) 1.03
Independent domains of inhibitory gating in schizophrenia and the effect of stimulus interval. Am J Psychiatry (2007) 1.02
Set-shifting ability and schizophrenia: a marker of clinical illness or an intermediate phenotype? Biol Psychiatry (2008) 1.00
Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord (2007) 1.00
Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry (2010) 1.00
Components of the smooth pursuit function in deficit and nondeficit schizophrenia. Schizophr Res (2003) 0.99
Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology (2003) 0.99
Beta (~16 Hz) frequency neural oscillations mediate auditory sensory gating in humans. Psychophysiology (2007) 0.99
Working memory consolidation is abnormally slow in schizophrenia. J Abnorm Psychol (2005) 0.98
Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch Gen Psychiatry (2006) 0.98
Spatial working memory as a cognitive endophenotype of schizophrenia: assessing risk for pathophysiological dysfunction. Schizophr Bull (2006) 0.97
Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q (2006) 0.97
A shared low-frequency oscillatory rhythm abnormality in resting and sensory gating in schizophrenia. Clin Neurophysiol (2011) 0.97
Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophr Bull (2010) 0.97
Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia. Am J Psychiatry (2002) 0.96
Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction. Schizophr Bull (2013) 0.94
The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry (2002) 0.94
Refining the predictive pursuit endophenotype in schizophrenia. Biol Psychiatry (2007) 0.93
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry (2009) 0.92
Impaired visual working memory consolidation in schizophrenia. Neuropsychology (2009) 0.92
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology (2013) 0.92
Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry (2003) 0.91
Antagonist-elicited cannabis withdrawal in humans. J Clin Psychopharmacol (2011) 0.91
Hypothetical decision making in schizophrenia: the role of expected value computation and "irrational" biases. Psychiatry Res (2013) 0.91
Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology (2007) 0.91
Is motion perception deficit in schizophrenia a consequence of eye-tracking abnormality? Biol Psychiatry (2008) 0.91
Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2009) 0.90
Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res (2008) 0.90
Association between polymorphism of the SNAP29 gene promoter region and schizophrenia. Schizophr Res (2005) 0.89
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res (2011) 0.89
Role of anticipation in schizophrenia-related pursuit initiation deficits. J Neurophysiol (2005) 0.89
Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull (2009) 0.89
Bupropion sustained release added to group support for smoking cessation in schizophrenia: a new randomized trial and a meta-analysis. J Clin Psychiatry (2011) 0.88
Tobacco craving in smokers with and without schizophrenia. Schizophr Res (2010) 0.87
Are structural brain abnormalities associated with suicidal behavior in patients with psychotic disorders? J Psychiatr Res (2013) 0.87
Cognitive endophenotypes of psychosis within dimension and diagnosis. Psychiatry Res (2012) 0.87
Smooth pursuit eye movement, prepulse inhibition, and auditory paired stimuli processing endophenotypes across the schizophrenia-bipolar disorder psychosis dimension. Schizophr Bull (2013) 0.86
Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res (2012) 0.86
Response to unexpected target changes during sustained visual tracking in schizophrenic patients. Exp Brain Res (2005) 0.85
Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr Res (2012) 0.85
Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders. Psychiatr Serv (2012) 0.85
Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol (2004) 0.85
Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res (2003) 0.85
Diet and sex hormones in boys: findings from the dietary intervention study in children. J Clin Endocrinol Metab (2006) 0.85
Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr Res (2008) 0.85
Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res (2008) 0.84
Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychiatr Res (2012) 0.84